Dr. Harrison is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
40 Duke Medicine Cir
Durham, NC 27710Phone+1 919-684-8111
Education & Training
University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 2007 - 2009
Tulane UniversityResidency, Internal Medicine, 2004 - 2007- Tulane University School of MedicineClass of 2004
Certifications & Licensure
NC State Medical License 2011 - 2025
WI State Medical License 2007 - 2011
LA State Medical License 2005 - 2007- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Start of enrollment: 2012 Dec 18
- RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017) Start of enrollment: 2014 Mar 01
- Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis Start of enrollment: 2015 Jul 01
Publications & Presentations
PubMed
- 39 citationsActive surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)Michael R. Harrison, Brian A. Costello, Nrupen A. Bhavsar, Ulka N. Vaishampayan, Sumanta K. Pal
Cancer. 2021-07-01 - 14 citationsCombination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and...Andrew Leonard Laccetti, Benjamin Garmezy, Lianchun Xiao, Minas Economides, Aradhana M. Venkatesan
Cancer Medicine. 2021-03-01 - 95 citationsFetal hydrops and death from sacrococcygeal teratoma: Rationale for fetal surgeryJacob C. Langer, Michael R. Harrison, Klaus G. Schmidt, Norman H. Silverman, Robert L. Anderson
American Journal of Obstetrics and Gynecology. 1989-05-01
Press Mentions
Immunotherapy Agents Improve Outlook for Advanced Bladder CancerAugust 13th, 2019
Cabozantinib RCC Benefit Highlighted as Frontline Approval ApproachesNovember 15th, 2017- Advanced RCC Results Point to Potentially New Frontline TreatmentsOctober 4th, 2017
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
